1. Home
  2. Directory
  3. New York
  4. Brooklyn
  5. Midwife
  6. NPI Profile
  7. Prescriptions 1417209651

MARYAM MIRZAAGHA C.M
Prescription History 1417209651
Midwife in Brooklyn, NY

NPI Status: Active since October 12, 2012

Contact Information

121 DEKALB AVE
BROOKLYN, NY
ZIP 11201
Phone: (718) 250-8000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MARYAM MIRZAAGHA C.M, an active Midwife specialist practicing in Brooklyn, NY. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 50 documented patient claims. Among these therapy options, the most frequently utilized medication is Fluconazole, which accounts for 26 claims alone.

Medication Index

C
F
M
No matching medications currently found on file.

Clotrimazole-Betamethasone

Generic Formulation: Clotrimazole/Betamethasone DipSpecialty: Midwife
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 192
NY State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply825
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $300.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.32

State Avg Cost Per Claim

$38.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat a variety of inflamed fungal skin infections such as ringworm, athlete's foot, and jock itch. This product contains 2 medications. Clotrimazole is an azole antifungal that works by preventing the growth of fungus. Betamethasone is a strong corticosteroid that works by reducing the swelling, redness, and itching that occurs in the skin infection. This medication is not recommended for children younger than 17 years or for diaper rash.

Fluconazole

Generic Formulation: FluconazoleSpecialty: Midwife
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 41
NY State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.6
Peer Average Days Supply277
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $78.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.00

State Avg Cost Per Claim

$35.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.

Therapeutic Applications

Fluconazole is used to treat vaginal yeast infections. It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals.

Metronidazole

Generic Formulation: MetronidazoleSpecialty: Midwife
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 74
NY State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.0
Peer Average Days Supply46
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $964.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$74.16

State Avg Cost Per Claim

$18.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.

Therapeutic Applications

This medication is used on the skin to treat a certain skin disorder known as rosacea, a type of adult acne. It may help to decrease redness, swelling and the number of pimples caused by rosacea. This medication is an antibiotic. For the treatment of rosacea, metronidazole is believed to work by decreasing swelling (inflammation). Some brands of this medication also contain sunscreens (see also Notes section).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MARYAM MIRZAAGHA C.M provides transparency into local medical care patterns within Brooklyn, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Midwife** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.